Ompi, the Italian glass primary packaging specialist for the pharmaceutical industry, has signed a collaboration agreement with SiO2 Medical Products (SMP).
The deal will enable pharmaceutical and biologics customers, contract filling organisations, and research laboratories to receive SMP’s proprietary primary containers in Ompi’s industry-recognised EZ-fill packaging configurations in trays, nest and tubs.
Ompi’s EZ-fill trays, and nest and tubs are designed to mitigate the risk of breakages, cosmetic issues, and particulate generation
Alabama-based SiO2 Medical Products, is a privately-owned company, developing and manufacturing precision-moulded containers. Its product line is made of engineered polymers, such as cyclic olefin polymer (COP), and incorporates a thin, transparent, silicon-based coating system composed of organosiloxane and silica nano-layers, which can also incorporate distinct surface properties.
Robert S. Abrams, Founder, CEO and Chairman of SMP, said: “We look forward to working with Ompi to fast-track the packaging, transportation, supply, and integration of SMP’s primary containers with existing fill-finish lines. Ompi’s industry-recognized EZ-fill® packaging configurations are often requested by our customers, and we are pleased to collaborate to make that request a reality.”
SMP said its new and patented coating system provides the durability and dimensional consistency of plastics with the oxygen barrier properties, ultra-low extractables, and pH stability of silica glass (i.e. quartz). The technology, the company said, brings together the best qualities of both plastics and glass containers, without their respective drawbacks, presents an innovative approach to primary packaging.
Contamination control
As part of the agreement, SMP’s primary containers will be supplied in Ompi’s industry-known packaging configurations, which readily integrate with existing fill-finish processing lines and accelerate the commercialisation of pharmaceuticals and biologics.
Validated to be shipped in quantities as low as a single carton, Ompi’s EZ-fill have been designed to offer a solution that can be extended from the clinical trial stage through to industrialisation.
Andrea Zambon, Marketing Director – Pharmaceutical Systems Division, Stevanato Group, Ompi’s parent company, said: “With the agreement with SMP, Ompi further strengthens its EZ-fill technology leadership and market positioning in secondary packaging. Thanks to our flexible, easy to use, and lean solution, clients can immediately integrate the EZ-fill packaging into their fill-finish lines to commercialise their therapies in the primary container of their choice, now including SMP’s proprietary primary containers.”
